Updates in the management of gout

被引:69
作者
Keith, Michael P. [1 ]
Gilliland, William R. [1 ]
机构
[1] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA
关键词
gout; management; colchicine; nonsteroidal anti-inflammatory agents; xanthine oxidase; probenecid; febuxostat;
D O I
10.1016/j.amjmed.2006.02.044
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The majority of patients with gout are cared for by primary care physicians. Although both the physician and patient may easily recognize the acute arthritis of gout, errors in selecting the most appropriate medication and proper dose are common. The clinical stages of gout include asymptomatic hyperuricemia, intermittent gouty arthritis, and chronic tophaceous gout. Treatment of gout is usually considered after the first attack of arthritis, typically podagra. The aims of treatment are to alleviate the pain and inflammation associated with acute attacks, prevent future attacks, and decrease uric acid levels. Confusion frequently arises because certain medications such as colchicine may have dual purposes: to treat an acute attack and to suppress future attacks. The purpose of this management update is to provide practical advice about prescribing the proper medication considering both treatment goals and patient comorbidities. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:221 / 224
页数:4
相关论文
共 10 条
[1]
Febuxostat compared with allopurinol in patients with hyperuricemia and gout [J].
Becker, MA ;
Schumacher, HR ;
Wortmann, RL ;
MacDonald, PA ;
Eustace, D ;
Palo, WA ;
Streit, J ;
Joseph-Ridge, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2450-2461
[2]
CHAMPION EW, 1987, AM J MED, V82, P421
[3]
Appropriateness of medication selection for older persons in an urban academic emergency department [J].
Chin, MH ;
Wang, LC ;
Jin, L ;
Mulliken, R ;
Walter, J ;
Hayley, DC ;
Karrison, TG ;
Nerney, MP ;
Miller, A ;
Friedmann, PD .
ACADEMIC EMERGENCY MEDICINE, 1999, 6 (12) :1232-1242
[4]
Fam AG, 2001, ARTHRITIS RHEUM-US, V44, P231, DOI 10.1002/1529-0131(200101)44:1<231::AID-ANR30>3.0.CO
[5]
2-7
[6]
Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis [J].
Getting, SJ ;
Christian, HC ;
Flower, RJ ;
Perretti, M .
ARTHRITIS AND RHEUMATISM, 2002, 46 (10) :2765-2775
[7]
The effects of vitamin C supplementation on serum concentrations of uric acid - Results of a randomized controlled trial [J].
Huang, HY ;
Appel, LJ ;
Choi, MJ ;
Gelber, AC ;
Charleston, J ;
Norkus, EP ;
Miller, ER .
ARTHRITIS AND RHEUMATISM, 2005, 52 (06) :1843-1847
[8]
A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy [J].
Shoji, A ;
Yamanaka, H ;
Kamatani, N .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2004, 51 (03) :321-325
[9]
Colchicine myotoxicity: Case reports and literature review [J].
Wilbur, K ;
Makowsky, M .
PHARMACOTHERAPY, 2004, 24 (12) :1784-1792
[10]
Recent advances in the management of gout and hyperuricemia [J].
Wortmann, RL .
CURRENT OPINION IN RHEUMATOLOGY, 2005, 17 (03) :319-324